ArticlemAbs2025
Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs.
Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma.Journal of translational medicine · 2026Article
- T-Cell Engagers in Lung Cancer: A Comprehensive Literature Review from Tarlatamab Approval to Next-Generation Strategies.Cancers · 2026Review
- From T cell engagers to next-generation immune cell engagers for cancer immunotherapy.Antibody therapeutics · 2026Review
- T cell engagers in autoimmune diseases.Nature reviews. Immunology · 2026Review
- Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell bispecific antibodies (TCBs) are an emerging class of cancer therapy that are typically designed for high binding affinity to CD3 and tumor antigen (TA). Using this approach, TCBs have demonstrated significant clinical efficacy, but they have also elicited cytokine release syndrome and off-target on-tumor toxicities. CD3 affinity-attenuation has recently been reported as an approach to maintain efficacy while reducing cytokine release, but the interdependence of CD3 affinity with other factors is often not systematically explored. For this purpose, we generated a series of TCBs comprising CD3 binders with varying affinities and TA binders with either high or low affinities, utilizing FOLR1 and CEACAM5 as tumor targets. The CD3 binders were classified into high, intermediate, low, and very low affine binders based on affinity measurements as well as functionality. Depending on the target, different combinations of binders showed the most advantageous profile of tumor-cell killing while coupled with lower cytokine secretion. For instance, within the FOLR1-TCBs series, CD3
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.